Placebo-corrected EASI75 (primary endpoint) of 52.6%, vs. 50% for leading atopic dermatitis (AD) biologic dupilumab (NCT01548404), hence convincing and warranting further development in our view.Ph2b start, as previously announced, still expected by end of the year.TP and Buy rating reiterated. Ph2a data of donzakimig, UCB's other AD biologic in development, still expected by YE.
